Navigation Links
Cyberonics Reports Strong Revenue Growth and Profitability in Fiscal 2008 Fourth Quarter
Date:6/11/2008

market test and/or regulatory approval of VNS Therapy(TM) for the treatment of other indications; satisfactory completion of post-market studies required by the U.S. Food and Drug Administration as a condition of approval for the treatment-resistant depression indication; adverse changes in coverage or reimbursement amounts by third-parties; intellectual property protection and potential infringement claims; maintaining compliance with government regulations and obtaining necessary government approvals for new indications; product liability claims and potential litigation; reliance on single suppliers and manufacturers for certain components; the accuracy of management's estimates of future expenses and sales; the results of the previously disclosed governmental inquiries; the potential identification of material weaknesses in our internal controls over financial reporting; risks and costs associated with such governmental inquiries and any litigation relating thereto or to our stock option grants, procedures, and practices (including the previously disclosed private litigation); uncertainties associated with stockholder litigation; and other risks detailed from time to time in our filings with the Securities and Exchange Commission (SEC). For a detailed discussion of these and other cautionary statements, please refer to our most recent filings with the SEC, including our Annual Report on Form 10-K for the fiscal year ended April 27, 2007.

Contact information

Greg Browne, CFO

Cyberonics, Inc.

100 Cyberonics Blvd.

Houston, TX 77058

Main: (281) 228-7262

Fax: (281) 218-9332

ir@cyberonics.com

CYBERONICS, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited except where indicated)

April 25, 2008 April 27, 2007


'/>"/>

SOURCE Cyberonics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Alfacell Reports Financial Results for Third Quarter of Fiscal 2008
2. YM BIOSCIENCES REPORTS NIMOTUZUMAB NSCLC CLINICAL DATA AT ASCO ANNUAL MEETING
3. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
4. Cord Blood America Reports CorCell, Its Major Acquisition in 2006, Turns Profitable
5. Bioheart, Inc. Reports Receipt of Notification from NASDAQ Regarding Non-Compliance with Continued Listing Requirements
6. Rosetta Genomics Reports First Quarter 2008 Financial Results
7. Genetic Engineering and Biotechnology News (GEN) Reports on Mass Spec in Drug Discovery
8. Advance Nanotech Reports First Quarter 2008 Financial Results
9. Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results
10. Senetek PLC Reports First Quarter 2008 Financial Results
11. New Study Reports That Ablative Therapy With HALO360 Device Effectively Treats Highest-Risk Category of Barretts Esophagus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... (PRWEB) November 25, 2014 The Pittcon ... its official conference and exposition mobile app, ... free download in the App Store for iOS and ... valuable resource tool before, during and after the event. ... details on exhibiting companies, technical sessions, Conferee Networking sessions ...
(Date:11/26/2014)... Boston, MA (PRWEB) November 26, 2014 ... and collaboration company is proud to announce that Darren ... Development and Sales. Darren will drive the ... and positive customer experience. , Darren brings ... He has held key roles in channel operations, from ...
(Date:11/26/2014)... TOKYO , 25 novembre 2014 Theravalues ... Super sur le marché européen au salon Hi ... Amsterdam ). Curcumine la ... une technologie amorphe (non-cristalline) à des ingrédients approuvés ... est un pigment jaune présent dans la racine ...
(Date:11/26/2014)... 2014  Roka Bioscience, Inc. (NASDAQ: ROKA ), ... for the detection of foodborne pathogens, today announced that ... 26 th Annual Healthcare Conference on December 2, 2014 ... New York Palace in New York, NY ... the Company, its operations, strategies and prospects may be discussed. ...
Breaking Biology Technology:Pittcon Releases 2015 Mobile App 2SoundConnect Appoints Director of Channel Development & Sales 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3Roka Bioscience to Present at the Piper Jaffray Healthcare Conference 2
... (Nasdaq: STAA ), a leading developer, manufacturer ... that the Afinity,Collamer(R) Aspheric foldable intraocular lens (IOL) ... Intraocular Lens (NTIOL) by the Centers for,Medicare and ... IOL,must first be an FDA approved IOL with ...
... Moody,s has raised the rating for the Gerresheimer ... As a result, the Group,s financial standing in ... Moody,s justifies,this step by reference to the considerably ... and in view of the Group,s increased,profitability and ...
... FRANCISCO, Calif., March 14 ,Renovis, Inc. (Nasdaq: RNVS ... of drugs for major medical needs in the areas ... fourth quarter and year ended December 31, 2007., ... December 31, 2007 was,$1.3 million and $9.8 million, respectively, ...
Cached Biology Technology:STAAR Surgical's Collamer(R) IOL Designated as a New Technology Intraocular Lens by the Centers for Medicare and Medicaid Services 2STAAR Surgical's Collamer(R) IOL Designated as a New Technology Intraocular Lens by the Centers for Medicare and Medicaid Services 3STAAR Surgical's Collamer(R) IOL Designated as a New Technology Intraocular Lens by the Centers for Medicare and Medicaid Services 4Moody's Raises Rating for Gerresheimer 2Renovis Reports Fourth Quarter and Full Year 2007 Financial Results 2Renovis Reports Fourth Quarter and Full Year 2007 Financial Results 3Renovis Reports Fourth Quarter and Full Year 2007 Financial Results 4Renovis Reports Fourth Quarter and Full Year 2007 Financial Results 5Renovis Reports Fourth Quarter and Full Year 2007 Financial Results 6Renovis Reports Fourth Quarter and Full Year 2007 Financial Results 7
(Date:11/5/2014)... Brazil -Individuals show great diversity in their ability to ... females greatly differ in their perceptual evaluation of odors, ... tests. , Sex differences in olfactory detection ... may be connected to one,s perception of smell, which ... women,s olfactory superiority has been suggested to be cognitive ...
(Date:11/4/2014)... In nature, the right amount of death at the ... density, according to new research that could help in ... wildlife stocks. , In a paper in the journal ... University researcher and European colleagues conclude that the kind ... a loss of individuals, or mortality, depends on the ...
(Date:11/4/2014)... 4, 2014) — Think about the way our bodies ... neighboring cells know that they are supposed to become ... these tissues find the correct place and alignment? Researchers ... crucial questions. , In a new study, UM researchers ... with their surrounding neighbors, at the head-trunk region. Their ...
Breaking Biology News(10 mins):The female nose always knows: Do women have more olfactory neurons? 2When less is more: Death in moderation boosts population density in nature 2The inside story: How the brain and skull stay together 2
... from Holzmaden (Germany) that perished 182 million years ago ... the extinct marine reptile is almost immaculately preserved and ... in their anatomical position. The bones of the ichthyosaur ... part, they lie scattered outside the body of the ...
... the number of retractions in scientific journals is just the ... dysfunction that has been evolving the world of biomedical research ... before a committee of the National Academy of Sciences (NAS) ... some behaviors that are detrimental to good science," says Ferric ...
... particular genetic variants may be more prone to fatty liver ... and adolescents in industrialized countries, according to new findings by ... on three ethnic groups, is published in the March issue ... Nicola Santoro, M.D., associate research scientist in the Department of ...
Cached Biology News:Exploding dinosaur hypothesis implodes 2Has modern science become dysfunctional? 2
... Tracker Intracellular Localization Kit provides a straight ... siRNA, of your design, in an efficient ... experiments. Subcellular localization and functional inhibition of ... introduction of the labeled siRNA into mammalian ...
... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
... Invasion Assay is designed to determine the ... a significant barrier to invasion or to ... a convenient, high-throughput, 96-well format. The 8 ... types of adherent cells such as epithelial, ...
... GrabIt™ Kits are designed for the study ... a pull-down method. Proteins that interact with ... fusion proteins are copurified using affinity resins ... retained on a spin filter. The complexes ...
Biology Products: